Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Zevra Therapeutics Inc (ZVRA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Zevra Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4.520 0.000    0.00%
26/04 - Closed. Currency in USD ( Disclaimer )
After Hours
4.520
0.000
0.000%
21:20:00 - Real-time Data
  • Volume: 157,431
  • Bid/Ask: 4.460 / 4.850
  • Day's Range: 4.480 - 4.600
Type:  Equity
Market:  United States
Zevra Therapeutics 4.520 0.000 0.00%

Zevra Therapeutics Company Profile

 
Read the Zevra Therapeutics Inc company profile to learn more about the business and the management team. View Zevra Therapeutics Inc facts about employee data, company products and services, and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

34

Equity Type

ORD

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Contact Information

Address 1180 Celebration Boulevard Suite 103
Celebration, 34747
United States
Phone 321 939 3416
Fax -
Web zevra.com

Top Executives

Name Age Since Title
Tamara A. Favorito 64 2021 Independent Chair
Donald R. Jasinski - - Member of Scientific and Medical Advisory Board
Srinivas Nalamachu - 2013 Co-Chair of Physician Advisory Council
Douglas W. Calder 57 2023 Independent Director
Thomas D. Anderson 68 2023 Independent Director
Wendy L. Dixon 69 2023 Independent Director
John B. Bode - 2023 Independent Director
Alvin Shih 47 2024 Independent Director
Corey M. Watton 54 2023 Independent Director
Robert Findling - - Member of Scientific & Medical Advisory Board
Barney Bishop - 2007 Chairman of Scientific and Medical Advisory Board
Jeffrey A. Gudin 58 2013 Co-Chair of Physician Advisory Council
Neil F. McFarlane 51 2023 President, CEO & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ZVRA Price Commentary

Write your thoughts about Zevra Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
John Klo
John Klo Mar 03, 2021 15:58
Saved. See Saved Items.
This comment has already been saved in your Saved Items
another pump and dumo
Giampaolo Cau
Giampaolo Cau Feb 04, 2021 12:32
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Time to go up!!!
Serhat Bakir
Serhat Bakir Jan 28, 2021 18:45
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Beautiful swing, just got approved by FDA! Target $30+ with $CLOV!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email